Evidence map›Paper›PMID 35209011›Full record

ArticleMolecules (Basel, Switzerland)2022

Assisting Multitargeted Ligand Affinity Prediction of Receptor Tyrosine Kinases Associated Nonsmall Cell Lung Cancer Treatment with Multitasking Principal Neighborhood Aggregation.

Fahsai Nakarin, Kajjana Boonpalit, Jiramet Kinchagawat, Patcharapol Wachiraphan, Thanyada Rungrotmongkol, Sarana Nutanong

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fahsai NakarinSchool of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong 21210, Thailand.ORCID 0000-0002-8221-2749
Kajjana BoonpalitSchool of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong 21210, Thailand.ORCID 0000-0002-9325-387X
Jiramet KinchagawatSchool of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong 21210, Thailand.
Patcharapol WachiraphanSchool of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong 21210, Thailand.ORCID 0000-0001-6484-7559
Thanyada RungrotmongkolCenter of Excellence in Biocatalyst and Sustainable Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0002-7402-3235
Sarana NutanongSchool of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong 21210, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multitargeted therapeutic approach with hybrid drugs is a promising strategy to enhance anticancer efficiency and overcome drug resistance in nonsmall cell lung cancer (NSCLC) treatment. Estimating affinities of small molecules against targets of interest typically proceeds as a preliminary action for recent drug discovery in the pharmaceutical industry. In this investigation, we employed machine learning models to provide a computationally affordable means for computer-aided screening to accelerate the discovery of potential drug compounds. In particular, we introduced a quantitative structure-activity-relationship (QSAR)-based multitask learning model to facilitate an in silico screening system of multitargeted drug development. Our method combines a recently developed graph-based neural network architecture, principal neighborhood aggregation (PNA), with a descriptor-based deep neural network supporting synergistic utilization of molecular graph and fingerprint features. The model was generated by more than ten-thousands affinity-reported ligands of seven crucial receptor tyrosine kinases in NSCLC from two public data sources. As a result, our multitask model demonstrated better performance than all other benchmark models, as well as achieving satisfying predictive ability regarding applicable QSAR criteria for most tasks within the model's applicability. Since our model could potentially be a screening tool for practical use, we have provided a model implementation platform with a tutorial that is freely accessible hence, advising the first move in a long journey of cancer drug development.

Indexed as

LigandsAlgorithmsCarcinoma, Non-Small-Cell LungDatabases, PharmaceuticalDrug DiscoveryHumansLung NeoplasmsMachine LearningProtein Kinase InhibitorsQuantitative Structure-Activity RelationshipReceptor Protein-Tyrosine KinasesReproducibility of ResultsSmall Molecule LibrariesWorkflowLigandsProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesSmall Molecule Librariesaffinity predictiondrug discoverymachine learningmultitaskingquantitative structure–activity relationship (QSAR)

Identifiers

PMID35209011
PMCPMC8878292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.